IL13 and keratitis: It highlights the need for both ophthalmologists and prescribing dermatologists/allergists to counsel patients carefully with respect to these medications, to treat early IL-13 inhibitor-associated ocular surface inflammation aggressively, and to be wary of potential progressive keratitis in patients receiving these therapies.